Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISAAC study for household contacts of invasive group A streptococcal disease
ACTRN12625000375459Phase 4Recruiting
- Sponsor
- University of Melbourne
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of azithromycin, cefalexin and Benzathine penicillin in Streptococcus pyogenes infection (4 arms), sponsored by University of Melbourne. Primary endpoint: Comparative effectiveness in clearance of pharyngeal group A Streptococcus. Started Dec 2025; status: recruiting.
02
Drugs
azithromycincefalexinBenzathine penicillin
03
Conditions
Streptococcus pyogenes infection
Beyond the preview
Go deeper on ACTRN12625000375459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000375459.